Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

205
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
205
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

394
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
394
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

117.2K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
117.2K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

11.6K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
11.6K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

miR-206-mediated Regulation in Depression: From Pathophysiological Mechanisms to Intranasal AntagomiR-206 Therapy.

CNS & neurological disorders drug targets·2026
Same author

The Important Role of miR-96 in Depression: New Research Progress and Future Prospects.

Current neuropharmacology·2026
Same author

A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPARγ receptors.

The international journal of neuropsychopharmacology·2024
Same author

Ginsenoside Rh2 administration produces crucial antidepressant-like effects in a CUMS-induced mice model of depression.

Brain and behavior·2022
Same author

A single nucleotide polymorphism in LRP2 is associated with susceptibility to Alzheimer's disease in the Chinese population.

Clinica chimica acta; international journal of clinical chemistry·2010
Same author

Three-component assembly and divergent ring-expansion cascades of functionalized 2-iminooxetanes.

Angewandte Chemie (International ed. in English)·2010

Related Experiment Video

Updated: Jun 15, 2025

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

478

GluN2A: A Promising Target for Developing Novel Antidepressants.

Gang Wang1, Wang Qi2, Qiu-Hua Liu1

  • 1Department of Hepatobiliary Surgery, Zhangjiagang Hospital affiliated to Soochow University/The First People's Hospital of Zhangjiagang City, Zhangjiagang, China.

The International Journal of Neuropsychopharmacology
|August 26, 2024
PubMed
Summary

Targeting the GluN2A N-methyl D-aspartate receptor (NMDAR) subunit offers a promising avenue for treating depression. Inhibiting GluN2A demonstrates resistance to stress-induced depressive behaviors, suggesting its therapeutic potential.

Keywords:
DepressionGluN2Aantidepressantsdepressive-like behaviorneurogenesis

More Related Videos

Animal Models of Depression - Chronic Despair Model CDM
05:47

Animal Models of Depression - Chronic Despair Model CDM

Published on: September 23, 2021

7.2K
Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

6.8K

Related Experiment Videos

Last Updated: Jun 15, 2025

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

478
Animal Models of Depression - Chronic Despair Model CDM
05:47

Animal Models of Depression - Chronic Despair Model CDM

Published on: September 23, 2021

7.2K
Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

6.8K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Depression is a complex mental health disorder with significant disability.
  • N-methyl D-aspartate receptor (NMDAR) modulators are investigated for depression treatment.
  • The role of the GluN2A NMDAR subunit in depression pathophysiology remains unclear.

Purpose of the Study:

  • To elucidate the function of the GluN2A subunit in depression.
  • To explore the link between GluN2A expression, neuroinflammation, and neurogenesis in depression pathogenesis.

Main Methods:

  • Review of existing literature on GluN2A and depression.
  • Summary of depression pathogenesis related to GluN2A expression regulation.
  • Analysis of GluN2A's interaction with neuroinflammation and neurogenesis.

Main Results:

  • Overexpression of GluN2A impairs synaptic plasticity, contributing to depression.
  • Selective antagonists targeting GluN2A subunits are crucial for therapeutic development.

Conclusions:

  • Specific inhibition of the GluN2A NMDAR subunit confers resistance to stress-induced depressive behaviors.
  • Targeting GluN2A presents a promising strategy for novel antidepressant development.